Syndax Pharmaceuticals, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 72.47 million compared to USD 39.19 million a year ago. Basic loss per share from continuing operations was USD 1 compared to USD 0.62 a year ago.

For the full year, the company reported net loss was USD 209.36 million compared to USD 149.34 million a year ago. Basic loss per share from continuing operations was USD 2.98 compared to USD 2.46 a year ago.